Richard Morgan is the Director of the University of
Bradford's Institute of Cancer Therapeutics in the UK
Image courtesy of U of Bradford
|
The study, published in the International Journal of Cancer, examined the role of HOX genes in ovarian cancer resistance to chemotherapy and whether a drug known as HXR9, which targets HOX, could help prevent the resistance from developing.